SGLT-2is Edge GLP-1 RAs on Foot Disease
Danish target trial emulation finds modest neuropathy benefit emerging following year 3, but high discontinuation rates complicate causal interpretation
By
Kerri Miller
January 5, 2026
1
SGLT-2 inhibitors showed a lower 6-year risk for diabetic foot disease compared to GLP-1 receptor agonists, with a risk ratio of 0.90.
2
The reduction in foot disease risk was primarily due to lower peripheral neuropathy risk among SGLT-2 inhibitor users.
3
No significant differences in other foot disease outcomes, such as peripheral artery disease and foot ulcers, were observed between the two groups.
4
SGLT-2 inhibitor users had a higher discontinuation rate, which may have influenced the study's findings and potential detection bias.
5
The study's results highlight the need for careful interpretation due to methodological limitations and the impact of treatment adherence.
